Stryker, a leading medical technology company based in Portage, Michigan, generates over $25 billion in annual revenue and serves more than 150 million patients. The company has consistently outperformed the broader medical technology industry, with organic revenue growth of about 10% annually over the past five years.
Its recent announcement of Spencer Stiles, a 27-year veteran, succeeding CEO Kevin Lobo, is seen as a positive leadership transition. Stryker's competitive advantage stems from its diverse organizational structure, comprising 22 specialized businesses, and a robust history of acquisitions, totaling around 60 in the last decade.
The company's position in robotic-assisted surgery, particularly with its Mako system, is expected to drive future growth, especially as demand for joint replacements rises with an aging population. Currently trading at approximately $304 per share, Stryker is about 23% below its 52-week high of $392.55 and is considered undervalued compared to its historical earnings multiples.
While risks include operational disruptions and changes in healthcare funding, the long-term growth potential, particularly in robotic surgery, presents an attractive opportunity for investors